Skip to content
StackItSmart
CCase reports / series
High riskCardiotoxicNeuropsychiatricHepatotoxic

Trenbolone Acetate

Tren A · Fina

Trenbolone acetate ("Tren A," "Fina") is a synthetic injectable anabolic-androgenic steroid (AAS) in the 19-nortestosterone/nandrolone family, sold only as a veterinary cattle growth implant and never approved, studied, or dosed in humans through any controlled trial. It is misused for muscle gain and fat loss. There is no human RCT or cohort data on it; everything known in people comes from case reports of harm and from animal studies. Trenbolone is a potent androgen (binds the androgen receptor roughly three times more strongly than testosterone) that strongly suppresses the body's own testosterone, is repeatedly linked in case reports to serious cardiovascular events (heart attack, sudden cardiac death, left-ventricular hypertrophy), pronounced neuropsychiatric effects (aggression, delirium, violence), acute pancreatitis, cholestatic liver injury, severe acne, gynecomastia, and worsened glucose control. Because it is an unregulated product of unknown purity and dose, injection-site infection and contamination add further risk. Anyone using or considering it should be under a physician's care with regular bloodwork; this monograph is educational only and not medical advice (21+).

Clinical readoutAAS · injectable-19nor
Hepatic strainModerate
CardiovascularHigh
HPTA suppressionVery high
Half-life
No formal human p…
Route
Intramuscular injection…
Evidence
C
Active
Estimated short
1·t½2·t½3·t½4·t½5·t½
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ No formal human pharmacokinetic studies exist. The acetate is a short-chain ester, so trenbolone acetate is pharmacologically short-acting relative to longer esters (enanthate); the active 17β-trenbolone and its metabolites are cleared over a matter of days. Exact human half-life values are not established.
Pharmacology

Mechanism of action

Trenbolone is 17β-hydroxyestra-4,9,11-trien-3-one, a synthetic 19-nortestosterone (nandrolone) derivative that acts as a potent agonist at the androgen receptor (AR), binding with roughly three times the affinity of testosterone. Unlike testosterone, it is not a substrate for 5α-reductase (so it is not converted to more potent androgens like DHT in prostate/skin) and it does not aromatize to estradiol; in animal models this produces a "tissue-selective," SARM-like profile with strong anabolic action on skeletal muscle and bone and comparatively less prostate growth at low doses. It is thought to also act by opposing glucocorticoid (catabolic) signaling and altering growth-factor activity. Despite not aromatizing, as a 19-nor compound it has progestogenic activity, which is the proposed mechanism for gynecomastia in users. The acetate ester is cleaved after injection to release the active 17β-trenbolone. Nearly all of this mechanistic detail derives from preclinical (rodent/in-vitro) work, not human study.
Kinetics

Pharmacokinetics

Half-life

No formal human pharmacokinetic studies exist. The acetate is a short-chain ester, so trenbolone acetate is pharmacologically short-acting relative to longer esters (enanthate); the active 17β-trenbolone and its metabolites are cleared over a matter of days. Exact human half-life values are not established.

Active duration

Estimated short (on the order of days per injection) based on ester chemistry and veterinary/forensic data rather than human PK trials; frequent re-injection is described in misuse. Parent compound is detectable far longer in keratinized matrices (hair, nails) than in blood/urine (a forensic detection window), documented here only for monitoring/washout reasoning and clinician discussion, never for evading testing.

Route

Intramuscular injection of an oil-based solution (a veterinary implant product diverted to human misuse).

Metabolism & clearance

Metabolized in the liver to less potent androgenic metabolites; because it is not 5α-reduced or aromatized, it does not form DHT or estradiol. Excreted via urine/feces. Detailed human clearance parameters are not characterized.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Marked increase in skeletal muscle mass and reduction in fat mass in animal models and reported by users (no controlled human efficacy data)
  • Potent androgenic signaling with strong suppression of endogenous testosterone
  • Reported improvements in body composition and lipid/insulin parameters in rodent studies — not demonstrated in humans and contradicted by real-world harm reports
  • Non-aromatizing but progestogenic, associated with gynecomastia despite no estrogen conversion
  • Frequently misused alongside other AAS, which confounds attribution of any single effect
Safety

Adverse effects by system

Cardiovascular

Case reports link trenbolone-containing AAS use to acute myocardial infarction in young men, sudden cardiac death, and left-ventricular hypertrophy; rodent lipid data show large HDL reductions. [41328125, 31499423, 33991187, 25554582]

Hepatic

Cholestatic hepatitis (jaundice, biopsy-confirmed) has been attributed to injectable trenbolone, countering the assumption that only oral 17-alkylated steroids are hepatotoxic. Rodent studies did not show overt hepatic injury, so human risk appears idiosyncratic/individual. [27937337, 25554582]

Endocrine / HPTA

Strong suppression of the hypothalamic-pituitary-testicular axis: low serum testosterone and testicular atrophy documented in a user; sex-hormone suppression confirmed in normogonadic rats. Worsened glucose control/new-onset diabetes reported (confounded by concurrent growth hormone and testosterone). [32872027, 25554582, 21558143]

Reproductive

Testicular atrophy and suppressed testosterone (impairing spermatogenesis/fertility) plus gynecomastia (via progestogenic activity) are reported/described; potential for infertility during use. [32872027, 38887114]

Neuropsychiatric

Prominent neuropsychiatric effects reported: aggression, hostility, delirium with psychosis requiring antipsychotics, and a homicide committed under acute trenbolone/metandienone influence. [32872027, 33813613]

Renal

No trenbolone-specific human renal outcome data. One case of rhabdomyolysis in a bodybuilder using trenbolone (among other drugs, including clenbuterol) had preserved renal function; AAS misuse generally is associated with kidney injury, but this is not established specifically for trenbolone. [16733985]

Hematologic

Erythrocytosis (elevated red cell mass) consistent with androgen use documented in a trenbolone case; also caused oil-solvent laboratory artifact (pseudohyponatremia) after inadvertent intravenous injection. Polycythemia raises thrombotic risk. [41492630]

Dermatologic

Severe acne, including acne fulminans, reported in bodybuilders using trenbolone-containing regimens; excessive body hair and stretch marks noted in review. [23069972, 38887114]

Recovery

HPTA suppression & recovery

Suppression: Severe

As a potent non-aromatizing androgen, trenbolone strongly suppresses endogenous testosterone; a user showed low serum testosterone with testicular atrophy, and rodent studies confirm sex-hormone suppression. Recovery of the hypothalamic-pituitary-testicular axis after stopping is variable and individual and can be prolonged, especially with 19-nor compounds and concurrent AAS. Any recovery plan should be directed by an endocrinologist; only single-SERM approaches are ever considered in the literature and dual-SERM protocols are out of scope here. Defer all recovery management to a qualified physician. [32872027, 25554582]

Bloodwork & vitals

Monitoring

Recommended labs & checks
Full lipid panel (HDL, LDL, triglycerides)Complete blood count with hematocrit/hemoglobin (screen for erythrocytosis)Blood pressureLiver function tests (ALT, AST, bilirubin, ALP)Fasting glucose and HbA1cTotal and free testosterone, LH, FSH, estradiol/prolactin (HPTA and gynecomastia workup)Renal function (creatinine, eGFR)Consider cardiac evaluation (ECG/echocardiography) given LVH and MI reports

Cadence: Establish a baseline before any use, then monitor periodically during use (e.g., every few weeks to a few months) and after discontinuation until parameters normalize, all under a physician's supervision. Any concerning symptom warrants immediate evaluation rather than waiting for scheduled labs.

Warning signs — seek care
  • Chest pain, shortness of breath, palpitations, or syncope (possible heart attack/arrhythmia — emergency)
  • Jaundice, dark urine, right-upper-quadrant pain, or severe nausea/vomiting (liver injury or pancreatitis)
  • Severe abdominal pain radiating to the back (acute pancreatitis)
  • New or worsening aggression, paranoia, confusion, mania, or suicidal thoughts
  • Severe headache, visual changes, or very high blood pressure
  • Excessive thirst/urination or very high blood glucose
  • Breast tenderness/enlargement, testicular shrinkage
  • Injection-site redness, swelling, pain, or fever (infection/abscess)
Do not use if

Contraindications

  • Not approved or intended for human use under any circumstances (veterinary product)
  • Pre-existing or family history of cardiovascular disease, hypertension, hyperlipidemia, or cardiomyopathy/left-ventricular hypertrophy
  • History of, or risk factors for, myocardial infarction or thrombosis (including baseline erythrocytosis/high hematocrit)
  • Liver disease or cholestasis
  • History of psychiatric illness, mood disorder, aggression, or psychosis
  • Diabetes or impaired glucose tolerance
  • Prostate hyperplasia or prostate/hormone-sensitive cancer
  • Pregnancy, breastfeeding, or possibility of pregnancy (virilization risk); anyone under 21 or not skeletally mature
  • Desire to preserve fertility or endogenous hormone function
Combinations

Interaction profile

  • MajorWith another anabolic steroid: Additive cardiovascular strain
  • MajorWith a thermogenic stimulant: Additive cardiovascular strain
  • ModerateWith thyroid hormone: Additive cardiovascular strain
  • ModerateWith growth hormone: Additive cardiovascular strain
  • MajorWith another anabolic steroid: Blood / clotting
  • MajorWith a clot-promoting SERM: Blood / clotting
  • ModerateWith an aromatase inhibitor: Hormonal
  • ModerateWith an anabolic steroid: Hormonal
  • ModerateWith another 19-nor (progestogenic) steroid: Hormonal
  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • This is a veterinary drug never tested in humans; the safest option is not to use it. If considering or using it, do so only with a physician's oversight and regular bloodwork.
  • Establish baseline labs (lipids, CBC/hematocrit, blood pressure, LFTs, glucose/HbA1c, testosterone/LH/FSH, renal function) before any use and monitor during and after.
  • Stop and seek emergency care for chest pain, breathlessness, palpitations, fainting, severe abdominal pain, jaundice, or sudden severe headache/visual change.
  • Seek help for new or worsening aggression, paranoia, confusion, mood changes, or suicidal thoughts. These neuropsychiatric effects are well documented and can endanger the user and others.
  • Product purity, dose, and even the actual compound are unknown in illicit veterinary preparations; injection carries infection, abscess, and contamination risk, and inadvertent intravascular injection can cause acute reactions.
  • Elevated hematocrit raises clot/stroke risk; do not ignore rising red-cell counts.
  • HPTA suppression can be severe and slow to recover; do not attempt self-managed hormonal 'recovery.' Any recovery plan (single-SERM approaches only are discussed in the literature) must be directed by an endocrinologist.
  • Combining trenbolone with other AAS or stimulants compounds cardiovascular and organ risk; polypharmacy also makes any problem harder to diagnose.
  • Educational information only, not medical advice; it does not create a doctor-patient relationship. 21+ only. Consult a qualified physician.
Evidence

Citations (16)

Every clinical claim above is tied to a primary source. Overall evidence grade C — graded to the best available evidence for its core claims.

  1. 01

    Trenbolone is 17β-hydroxyestra-4,9,11-trien-3-one, binds the androgen receptor with ~3x the affinity of testosterone, is not 5α-reduced and does not aromatize, giving a tissue-selective/SARM-like anabolic profile with less prostate growth (mechanism; preclinical/review).

    ReviewTissue selectivity and potential clinical applications of trenbolone (17beta-hydroxyestra-4,9,11-trien-3-one): A potent anabolic steroid with reduced androgenic and estrogenic activity.PMID 20138077 ↗

  2. 02

    In rodents, trenbolone increases muscle and bone and reduces adiposity while sparing prostate and hemoglobin at low doses (tissue-selective anabolic activity; preclinical).

    Preclinical17beta-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate.PMID 21266670 ↗

  3. 03

    In normogonadic rats trenbolone improved body composition and insulin sensitivity and markedly lowered serum lipids (HDL/LDL/triglycerides) but suppressed sex hormones and caused benign prostatic hyperplasia; no overt cardiac or hepatic injury seen (preclinical basis for lipid and HPTA-suppression concerns).

    PreclinicalImprovements in body composition, cardiometabolic risk factors and insulin sensitivity with trenbolone in normogonadic rats.PMID 25554582 ↗

  4. 04

    Acute myocardial infarction in a 35-year-old bodybuilder using trenbolone acetate with testosterone and nandrolone (cardiovascular harm; human case report).

    Case reportAcute Myocardial Infarct in a Young Bodybuilder Taking Anabolic Steroids: A Case Report.PMID 41328125 ↗

  5. 05

    Sudden death with left-ventricular hypertrophy and small coronary lumen in a young AAS user whose panel included trenbolone (cardiac harm; human forensic case report).

    Case reportDeath after misuse of anabolic substances (clenbuterol, stanozolol and metandienone).PMID 31499423 ↗

  6. 06

    Sudden cardiac death in the context of repetitive anabolic steroid abuse including trenbolone, documented by hair analysis (cardiac harm; human forensic case report).

    Case reportIn a Case of Death Involving Steroids, Hair Testing is More Informative than Blood or Urine Testing.PMID 33991187 ↗

  7. 07

    Biopsy-confirmed cholestatic hepatitis attributed to injectable trenbolone (enanthate), showing injectable trenbolone can be hepatotoxic (human case report).

    Case reportA jaundiced bodybuilder Cholestatic hepatitis as side effect of injectable anabolic-androgenic steroids.PMID 27937337 ↗

  8. 08

    Recurrent acute pancreatitis attributed to trenbolone acetate, confirmed by rechallenge on reuse (human case report).

    Case reportAcute pancreatitis secondary to the use of the anabolic steroid trenbolone acetate.PMID 30101635 ↗

  9. 09

    Anabolic-steroid-induced delirium with aggression and psychosis in a user of testosterone and trenbolone acetate, with low serum testosterone and atrophic testes (neuropsychiatric and HPTA-suppression harm; human case report).

    Case reportAnabolic steroids-induced delirium: A case report.PMID 32872027 ↗

  10. 10

    Homicide committed under acute influence of trenbolone and metandienone after chronic use, linking trenbolone to extreme aggression/violence (neuropsychiatric harm; human forensic case report).

    Case reportAnabolic steroids and extreme violence: a case of murder after chronic intake and under acute influence of metandienone and trenbolone.PMID 33813613 ↗

  11. 11

    Acne fulminans (severe acne) induced by anabolic steroids including trenbolone in a male bodybuilder (dermatologic harm; human case report).

    Case reportThe dark side of beauty: acne fulminans induced by anabolic steroids in a male bodybuilder.PMID 23069972 ↗

  12. 12

    Review noting trenbolone users commonly experience severe acne and gynecomastia (~one-third), excessive body hair, stretch marks, hypertension, cardiac arrhythmia, and injection-site inflammation/fibrosis/necrosis (multi-system adverse effects; review).

    ReviewImpact of trenbolone on selected organs.PMID 38887114 ↗

  13. 13

    New-onset diabetes/hyperglycemia in a bodybuilder self-injecting trenbolone acetate with testosterone and growth hormone (glucose-metabolism harm, confounded by co-administration; human case report).

    Case reportNew onset diabetes associated with bovine growth hormone and testosterone abuse in a young body builder.PMID 21558143 ↗

  14. 14

    Rhabdomyolysis in a bodybuilder using trenbolone among other agents (including clenbuterol) with preserved renal function; illustrates acute muscle injury but not trenbolone-specific nephrotoxicity (human case report).

    Case report[Rhabdomyolysis in a bodybuilder using steroids].PMID 16733985 ↗

  15. 15

    Erythrocytosis consistent with anabolic steroid use, and an oil-solvent laboratory artifact (pseudohyponatremia) after inadvertent intravenous trenbolone injection (hematologic effects; human case report).

    Case reportWhen the Numbers Lie: Uncovering Pseudohyponatremia After an Anabolic Steroid Injection.PMID 41492630 ↗

  16. 16

    Trenbolone protected against cardiometabolic risk factors and myocardial ischemia-reperfusion injury in testosterone-deficient metabolic-syndrome rats, but testosterone/androgen exposure caused prostate hyperplasia — context that these apparent benefits are preclinical only (preclinical).

    PreclinicalTrenbolone Improves Cardiometabolic Risk Factors and Myocardial Tolerance to Ischemia-Reperfusion in Male Rats With Testosterone-Deficient Metabolic Syndrome.PMID 26584015 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice